Kymazol (Simvastatin)

Simvastatin inhibits the enzyme HMG‑CoA reductase, which is essential for cholesterol synthesis in the liver. By blocking this pathway, the drug reduces hepatic cholesterol production, leading to an increase in LDL‑receptor expression on liver cells and enhanced removal of LDL‑cholesterol from the bloodstream.

The appropriate dose of Kymazol is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk, and tolerance. Dosage adjustments are individualized, and patients should follow the specific instructions provided by their healthcare professional.

Simvastatin is generally contraindicated during pregnancy and lactation because cholesterol synthesis is essential for fetal development. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative lipid‑lowering strategies with their physician.

To place an order, submit an enquiry on the Kymazol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kymazol (simvastatin) is a moderately potent statin with a well‑established efficacy and safety profile. Compared with higher‑intensity agents such as atorvastatin or rosuvastatin, simvastatin may achieve slightly lower LDL‑cholesterol reductions at equivalent doses, but it remains a cost‑effective option for many patients.

Kymazol should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Kymazol is taken orally, usually once daily in the evening with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew it.

The most serious adverse reactions include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney failure, and significant liver enzyme elevations indicating hepatotoxicity. Patients should promptly report unexplained muscle pain, weakness, or dark urine, and any signs of liver dysfunction.

Kymazol is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, known hypersensitivity to simvastatin or any excipients, and in patients who are pregnant or breastfeeding. It should also be avoided in patients taking strong CYP3A4 inhibitors unless the prescriber decides otherwise.